ArticleMolecules (Basel, Switzerland)2026
Development of an Integrated CE-Cell-SELEX Strategy for Rational Selection of Human Bone Microvascular Endothelial Cell Aptamers.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Capillary electrophoresis (CE) has proven to be an effective technique for aptamer selection. Here, we directly integrated the separation advantages of CE into a live-cell system, thereby establishing an integrated and highly efficient CE-Cell-SELEX screening model for bone microvascular endothelial cells (BMECs) without the need for negative selection. The selection progress was monitored through quantitative real-time fluorescence PCR (qRT-PCR) analysis, which yielded 7 candidate sequences from the amplified library after four rounds of selection. Flow cytometry analysis demonstrated that aptamer T-24 exhibited high affinity for BMECs, with a Kd of 111.86 ± 18.36 nM. Owing to its high affinity and specificity, coupled with its small molecular weight and non-immunogenicity, T-24 holds great potential as a biological probe for the identification and isolation of BMECs. Furthermore, molecular docking was performed by MOE 2022 software to validate the candidate sequences and assist in the identification process. The CE-Cell-SELEX method eliminates the need for negative screening and traditional elution, greatly reduces the screening cycle, and may provide a valuable reference system for the early diagnosis and precise treatment of femoral head ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.